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Vi capsular polysaccharide (Vi) conjugate vaccines, which can prevent typhoid in infants and young children, are
being developed. Comparative immunogenicity studies are facilitated by an International Standard (IS) for
human anti-Vi IgG. 16/138, a pool of sera from volunteers which received either Vi conjugate vaccine or plain Vi
vaccine, was assessed as an IS alongside U.S. reference reagent Vi-IgGR1, 2011. Samples were tested in a com-
mercial ELISA (n=7), a standardised ELISA based on biotinylated Vi (n=7) and in-house ELISAs (n=7). Valid
estimates were obtained for the potency of all samples in the commercial ELISA, and the commutability of 16/
138 and Vi-IgGR1, 2011 was evident for the commercial ELISA and in-house ELISAs based on a coating of Vi and
protein. The WHO Expert Committee on Biological Standardization established 16/138 as the first IS for anti-Vi
IgG with 100 IU per ampoule and assigned 163 IU per vial of Vi-IgGR1, 2011.
1. Introduction
Typhoid fever is caused by an infection with Salmonella enterica
subspecies enterica serovar Typhi. S. Typhi expresses a capsular poly-
saccharide, Vi, which is a virulence factor and considered the main
protective antigen [1,2]. In developing countries, typhoid disease af-
fects in particular children and young adults and is a considerable cause
of morbidity and mortality. A recent study estimated a global incidence
of 12 million cases of typhoid and 129,000 deaths each year [3].
Vaccination is the most cost effective preventative strategy to con-
trol typhoid fever in endemic areas and in areas where anti-microbial
resistant strains reside. However, oral live attenuated Ty21a vaccine
and the injectable plain Vi vaccine, which is prequalified by the WHO,
are not suitable for use in children under five and two years of age
respectively, and plain Vi vaccines are unable to induce a booster re-
sponse in adults and children [4–6]. Early studies of Haemophilus in-
fluenzae polysaccharide vaccines showed that the latter issue was suc-
cessfully addressed by conjugation of the polysaccharide to a carrier
protein, usually a bacterial toxoid [7,8]. A prototype typhoid conjugate
vaccine (TCV) consisting of Vi conjugated to recombinant Pseudomonas
aeruginosa exoprotein A (Vi-rEPA) was proven to be immunogenic and
induced a booster response in young children [9]. A double-blind ran-
domized clinical trial of Vi-rEPA in 2–5-year olds revealed the vaccine
to be safe and efficacious [10]. Vi-rEPA also induced a long lasting anti-
Vi IgG response in pre-school age children and infants [11]. Recently,
two Vi tetanus toxoid conjugate vaccines (Vi-TT) were licensed in India
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[12,13]. Currently, 10 TCVs using a variety of carrier proteins for
conjugation of Vi are in development: three vaccines are in clinical
trials and three vaccines are approaching licensure (personal commu-
nication, S. Sahastrabuddhe).
The first international reference serum TYS, a freeze dried anti-Vi
serum from a horse immunised with rough and smooth S Typhi, was
made available in 1935 [1,14]. In 2009, the WHO Expert Committee on
Biological Standardization of WHO (ECBS) asked the National Institute
for Biological Standards and Control (NIBSC) to produce a human anti-
Vi IgG serum standard to replace TYS. In 2010, candidate replacement
10/126, a freeze dried pool of sera from clinical trial volunteers who
had been immunised with two doses of a Vi-TT (Typbar TCV™, Bharat
Biotech International Ltd, India) was produced [15].
In 2012, a WHO working group discussed the need for a regulatory
framework to evaluate TCVs, compare clinical trial studies and analyse
the safety, consistency and potency of TCVs by calibrated physico-
chemical assays and immunoassays. This resulted in the WHO guide-
lines on the quality, safety and efficacy of TCVs, which confirmed the
need for reference materials for Vi and human anti-Vi serum [16,17]. In
2013, Vi PS lot 05 and Vi-IgGR1, 2011 were established as U.S. reference
reagents for Vi and human anti-Vi IgG respectively. Vi-IgGR1, 2011 is a
purified fraction of IgG from plasma donations by volunteers vaccinated
with Vi-rEPA and contains 33 μg anti-Vi IgG mL−1 or 26.6 ELISA Units
mL−1 [18].
The WHO working group proposed a collaborative study (CS) to
evaluate the performance of both Vi-IgGR1, 2011 and candidate
International Standard (IS) 10/126 to avoid potential confusion in the
future [16]. Their performance was consistent in the commercial
VaccZyme Human Anti-Salmonella typhi Vi IgG ELISA (Binding Site,
UK), but results from in-house ELISAs were highly variable [15]. A
review by ECBS concluded that reliance on a commercial ELISA com-
bined with the paucity of data about this assay provided insufficient
evidence to establish 10/126 as a WHO IS. ECBS requested: a clar-
ification of the inter- and intra-laboratory variation among in-house
ELISAs; a new set of anti-Vi positive sera from a clinical trial to establish
commutability of both reference reagents; and the establishment of a
reliable non-commercial Vi ELISA [15,19].
Previous studies reported poor binding of bacterial polysaccharides
such as Vi to the micro-plate surface as a cause for inconsistent ELISA
results. This was mitigated by a pre- or co-coating of the polysaccharide
with a protein or by chemical modification of the polysaccharide
[20–22]. Ferry et al. showed that an ELISA based on biotinylated Vi
provided a specific and sensitive screen for anti-Vi IgG in naïve and
vaccinated individuals [23]. This observation informed the develop-
ment of an in-house biotinylated Vi ELISA described here and desig-
nated NIBSC ELISA.
In collaboration with the Oxford Vaccine Group (OVG), sera from
volunteers immunised with either a WHO prequalified and licensed
plain Vi vaccine or a WHO prequalified and licensed Vi-TT conjugate
vaccine as described by Jin et al. were obtained [24]. These sera were
pooled and freeze dried to produce 16/138 and a quality control (QC)
panel made up of individual pre- and post-vaccination sera.
The intended use of 16/138 is to benchmark Vi ELISAs used to
evaluate clinical trials to allow a comparison of the immunogenicity of
various TCVs. The main aim of the CS was to assess the suitability of
16/138 to serve as a WHO IS for anti-Vi PS IgG (human) in various
ELISAs. The second aim was to assign a unitage to 16/138 and a relative
unitage to Vi-IgGR1, 2011 and 10/126, which remains available at
NIBSC. Thirdly, the commutability of 16/138 was assessed with in-
dividual anti-Vi PS IgG sera from the QC panel and finally the perfor-
mance and reproducibility of the NIBSC ELISA alongside the commer-
cial VaccZyme ELISA was assessed across multiple laboratories.
2. Materials and methods
2.1. Participating laboratories and assay codification
Seven participants, including vaccine manufacturers, national con-
trol laboratories and research laboratories from six countries tested the
study samples and supplied data for this study (see acknowledgments
section for details). Throughout the study, laboratories were identified
by a randomly assigned code number to maintain confidentiality. Data
were collected and analysed at NIBSC. Six unique plate layouts for the
assay runs were provided in the study protocol.
2.2. Samples used in the collaborative study
Each participant received a sample set comprising one ampoule of
16/138, coded ampoules (A-F), and one ampoule of Vi-IgGR1, 2011,
supplied by the Center for Biologics Evaluation and Research (CBER) of
the Food & Drug Administration of the Department of Health and
Human Services, USA (see Table 1). In addition, essential reagents for
the NIBSC ELISA and 6 VaccZyme human anti-Salmonella Typhi Vi IgG
ELISA kits (Binding Site, UK) were included. These reagents were ac-
companied by instructions for use, material safety data sheets, and a
standard operating procedure for the NIBSC ELISA and manufacturer's
instructions for the commercial ELISA. A brief characterisation of the
study samples, study codes, NIBSC codes and their reactivity in the
VaccZyme ELISA is given in Table 1. All samples tested negative for
antibodies to HIV 1/2 and hepatitis C and hepatitis B surface antigen.
Freeze dried samples 16/138 and A to F were reconstituted as described
in the Instructions for Use. The production and characterisation of Vi-
IgGR1, 2011 is provided in detail by Szu et al. [18]. This reference re-
agent was reconstituted as described in the product circular. Reagents
for the NIBSC ELISA consisted of one ampoule of 5mg purified strep-
tavidin from Streptomyces avidinii (S4762, Sigma-Aldrich), one ampoule
of 1mg freeze dried biotinylated Vi derived from Citrobacter freundii
(NIBSC12/244; Innova Biosciences), and one ampoule of goat anti-
Human IgG horse radish peroxidase (HRP) conjugate (A8667, Sigma-
Aldrich). All samples were sent on dry ice, with the exception the
Table 1
Characterisation of samples used in this study.
Study code NIBSC code Description Reactivity in the VaccZyme ELISA
16/138 – Pooled Anti-Vi IgG sera from 16 volunteers 631 UmL−1a
Vi-IgGR1, 2011 – Purified Anti-Vi IgG from 5 volunteers 1280 UmL−1b
A 10/126 Pooled Anti-Vi IgG sera from 9 volunteers 842 UmL−1c
B 16/150 Post-Typbar TCV vaccination serum 350 UmL−1c
C 16/138 Pooled Anti-Vi IgG sera from 16 volunteers 631 UmL−1a
D 16/144 Post-Vi PS vaccination serum 345 UmL−1c
E 16/146 Post-Vi PS vaccination serum 524 UmL−1c
F 16/140 Pre-Vaccination serum 22 UmL−1c
a Based on an estimate from 3 runs.
b Based on an estimate from 4 runs.
c Based on an estimate from one run.
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VaccZyme ELISA kits sent at 2–8 °C.
2.3. Characterisation of 16/138
Sera from vaccinated volunteers, as described below, were supplied
by OVG. Ethical approval was obtained from South Central Oxford A
Ethics Committee (14/SC/1427) and the protocol was approved by the
Medicines and Healthcare Products Regulatory Agency (Eudract 2014-
002978-36). The Human Materials Advisory Committee of NIBSC (16/
004SR) approved the use of these sera as a source for 16/138.
In brief, consenting healthy volunteers (age range 18–57 years)
received one dose of either plain Vi (Typhim Vi™, Sanofi Pasteur; Vi-PS;
n=15) or Vi-TT (Typbar TCV™; TCV; n=14). Sera were collected
prior to vaccination and 4–6 weeks post-vaccination. This vaccination
schedule closely resembled the schedule used in an assessment of vac-
cine efficacy using a controlled human infection model in which both
plain Vi-PS and TCV were evaluated [24]. Frozen sera were transferred
to NIBSC and stored at −80 °C until further use. Individual pre- and
post-immunisation sera were tested for anti-Vi IgG in the VaccZyme
ELISA and the NIBSC ELISA. Post-vaccination sera which showed a> 3-
fold increase in ELISA Units in both assays were selected as source
material for 16/138 (results not shown). Seven sera from volunteers
vaccinated with Vi-PS and 9 sera from volunteers vaccinated with TCV
were pooled. The pool of approximately 3 L was dispensed in 1.0 mL
aliquots into glass ampoules coded 16/138. The mean fill weight for 98
ampoules was 1.007 g (CV of 0.21%). On the same day, freeze-drying
under vacuum started and was completed after four days. Ampoules
were back filled with pure N2 (moisture content< 10 ppm). Residual
moisture, measured by the Karl-Fischer method, for 12 ampoules was
0.5246% (CV of 6.92%). An integrity test was not performed; however,
the oxygen level in the headspace of 12 ampoules was checked and
found to be 0.39% (CV of 29.97%). This implies these ampoules passed
a test for integrity because the presence of cracks would be associated
with an oxygen level of around 20%, similar to that found in the at-
mosphere. Twelve ampoules were rejected during the production pro-
cess, 30 ampoules were held for accelerated degradation studies and
2551 ampoules were stored at −20 °C. The fill of 16/138 met the WHO
criteria for ISs [25]. The ampoules are available for distribution by
NIBSC. The effect of freeze drying on levels of specific anti-Vi IgG was
determined by NIBSC ELISA in liquid and freeze dried samples of 16/
138. The freeze-drying process did not affect the anti-Vi IgG titre (see
Fig. 1).
2.4. Characterisation of coded sera
Twelve individual pre- and post-vaccination sera of volunteers,
immunised with Vi-PS or TCV and representing a range of anti-Vi IgG
levels, were used to assemble a serum panel. Sera were dispensed in 80
ampoules as 1.0mL aliquots, freeze dried and stored at −20 °C until
further use. Four sera were selected as test samples coded B, D, E and F
(see Table 1).
2.5. Characterisation of 10/126
Approximately 1 L of human serum was collected from 9 consenting
volunteers (24–30 years old) who had received two doses of TCV as part
of a phase II clinical trial (see Table 1 [15]). The vaccinations were
given 4 weeks apart and sera were collected at week 6 after the booster
and frozen. The use of source material for candidate IS 10/126 was
approved by the Human Materials Advisory Committee of NIBSC
10_002SR. At NIBSC, samples were thawed and pooled. The serum pool
was dispensed as 0.5mL aliquots into glass ampoules coded 10/126.
The mean fill weight for 78 ampoules was 0.5181 g (CV of 0.19%). On
the same day, freeze-drying under vacuum started and was completed
after four days. Ampoules were back filled with pure N2 (moisture
content< 10 ppm). Residual moisture, measured by the Karl-Fischer
method, for 6 ampoules was 0.23% (CV of 17.60%). An integrity test
was not performed; however the oxygen level in the headspace of 12
ampoules was checked and found to be 0.59% (CV of 29.55%). Twenty-
six ampoules were rejected during the production process, 44 ampoules
were held for accelerated degradation studies and 1654 ampoules are
stored at −20 °C and available for distribution by NIBSC. Freeze drying
had no effect on the titre of IgG directed against Vi in 10/126 [15].
2.6. ELISAs
Study samples were tested in the VaccZyme ELISA and eight in-
house ELISAs. The ELISA code and a brief description of the coating
procedure are given in Table 2. Two ELISA formats were made available
to all participants: the VaccZyme ELISA based on native S Typhi Vi, and
the NIBSC ELISA based on a streptavidin-biotinylated C freundii Vi
complex. All participants performed the NIBSC ELISA, the commercial
Vacczyme ELISA as well as their in-house ELISA. ELISA procedures are
given below. Six different plate layouts were provided to the partici-
pants and samples were tested repeatedly in 6 runs, except for La-
boratory 2 (4 runs for the Vacczyme ELISA and 2 runs for their in-house
ELISA) and Laboratory 6 (5 runs for the Vacczyme ELISA). Each par-
ticipant was asked to prepare starting dilutions of sera and reference
reagents of 1:100 in appropriate assay diluents, with the exception of
16/138, which had a starting dilution of 1:25. A description of the
ELISA procedure accompanied the raw data returned by the participant
for analysis.
2.6.1. VaccZyme ELISA
The VaccZyme ELISA was carried out according to the manufac-
turer's instructions (Binding Site). The VaccZyme ELISA is based on Vi
of S. Typhi. Five calibrators, covering a range from 7.4, 22.2, 66.7, 200
and 600 EU mL−1, and a high and a low positive control were included
in each run. The assay has a sensitivity of 7.4 EU mL−1. Plates were
read at OD450nm.
2.6.2. NIBSC ELISA
This in-house ELISA, developed at NIBSC, follows the procedure
described by Ferry et al. with minor modifications [23]. The plate
surface is coated with streptavidin to capture biotinylated Vi from C
freundii (NIBSC 12/244; Innova Biosciences). For this purpose, ap-
proximately 20 ampoules with a solution of 1mg biotinylated Vi from C
freundii and 10mg Trehalose (a cryopreservant) were freeze dried and
stored at −20 °C at NIBSC until distribution among participants. Wells
of a micro-titre plate (Nunc MaxiSorp) were pre-coated with 100 μL of
5 μg Streptavidin mL−1 (Sigma Aldrich, S4762) in sterile water and
incubated uncovered overnight at 37 °C. The content of one ampoule
with freeze dried biotinylated Vi was reconstituted overnight at 4 °C
with 1mL Mill-Q water. On the following day, 3 μg biotinylated Vi
Fig. 1. Titration of anti-Vi IgG in liquid (△) and freeze dried (■) formulations
of 16/138 by the NIBSC ELISA.
S. Rijpkema et al. Biologicals 56 (2018) 29–38
31
mL−1 was prepared from stock in PBS, 100 μL was added to wells of a
streptavidin-coated plate and incubated for 3 h at 37 °C. Plates were
washed three times and 250 μL Blocking Buffer 1 (BB1: 10% non-fat dry
milk (w/v) in PBS (pH 7.3–7.5) was added to each well. Plates were
incubated for 2 h at 4 °C and washed 3x with PBS-Tween 0.05% (PBS-
T). Sera and reference reagents were diluted in Assay Diluent 1 (AD1;
0.05% Tween-20 in BB1). 200 μL each of starting dilutions was added to
appropriate wells and 100 μL AD1 was added to the remaining wells.
Doubling dilutions were performed on the plate. Plates were covered
and incubated for 2 h at RT (range 20–25 °C) and washed 3x with PBS-
T. 100 μL of HRP conjugated goat anti-human IgG (Sigma Aldrich,
A8667) diluted 1:10,000 in AD1 was added to each well. Plates were
covered, incubated for 1 h at RT and washed 3x with PBS-T. 100 μL of
TMBlue substrate (Leinco Technologies) was added to each well. Plates
were developed in the dark for 10mins and the reaction was stopped
with 50 μL H2SO4 per well. Plates were read at OD450nm.
2.6.3. In-house ELISA 1
The ELISA carried out by Laboratory 1, is a modification of the
ELISA described by Szu et al. [18]. Nunc Maxisorp plates are pre-coated
of with Poly-L-Lysine hydrobromide (Sigma, P1399) followed by a coat
with Vi from S. Typhi (SK chemicals, CT1S0153) [26]. 100 μL of 10 μg
poly-L-Lysine mL−1 in PBS was added to the wells, incubated at RT for
2 h and washed 6x with 0.85% NaCl and 0.1% Brij35 in ultrapure water
(NaCl-Brij 35). 100 μL of 2 μg Vi mL−1 in PBS was added to the wells.
Plates were incubated overnight at 37 °C and washed 6x with NaCl-Brij
35. 250 μL BB2 [1% BSA in PBS) was added to each well. Plates were
incubated for 1 h at 37 °C and washed six times. Dilutions of test sam-
ples were prepared in AD2 (BB2 with 0.1% Brij35). Then 100 μL of
diluted tested sample was dispensed to appropriate wells of the plate.
Samples were incubated at 37 °C for 1 h and washed 6x with NaCl-Brij
35. Then 100 μL of alkaline-phosphatase (AP) conjugated mouse anti-
human IgG Fc (Abcam, AB99764) diluted 1:2000 in AD2 was added to
each well, incubated at 37 °C for 1 h and washed 6x with NaCl-Brij 35.
100 μL 4-Nitrophenyl Phosphate disodium salt hexahydrate substrate
(Sigma) in Tris/3mM Mg-buffer (pH 9.8) was added per well and in-
cubated at RT in dark for 1 h, followed by the addition of 50 μL 3M
NaOH stop solution to each well. The plate was read at 405 nm and
490 nm. Background OD490 was subtracted from OD405.
2.6.4. In-house ELISA 2
The procedure carried out by Laboratory 2 uses Vi from C. freundii
produced in–house. Wells were coated with 100 μL of 4 μg Vi mL−1
diluted in PBS and incubated overnight at 2–8 °C. Nunc MaxiSorp plates
were washed 1x with PBS-T using a plate washer and plates were
tapped dry on tissue paper. Wells were blocked with 200 μL BB3
(PBS + 5% skimmed milk) and incubated at RT for 1 h. Plates were
washed 3x with PBS-T. Sera were diluted in AD3 (PBS-T + 0.1% BSA)
and 100 μL of each dilution was added to wells in duplicate. Plates were
incubated at RT for 2 h and washed 3x with PBS-T. Goat anti Human
IgG-AP (Sigma-Aldrich, A9544) was diluted 1:15,000 in AD3 and
100 μL was added to each well. Plates were incubated at RT for 1 h.
Plates were washed 5x with PBS-T. 4-Nitrophenyl Phospate liquid
substrate (Sigma-Aldrich, N-7653) was warmed to RT and 100 μL was
added per well. Plates were incubated at RT for 1 h. The reaction was
stopped by adding 100 μL of 2M NaOH to each well. The plate was read
at 405 nm and 490 nm. Background OD490 was subtracted from OD405.
2.6.5. In-house ELISA 3
The procedure carried out by Laboratory 3 is based on the ELISA
described by Szu et al. and uses Vi lot 05 supplied by CBER [18]. Wells
(Nunc Maxisorp) were coated with 100 μL of 2 μg Vi mL−1 diluted in
PBS. Plates were covered, incubated overnight at 25 °C, washed 2x with
NaCl-Brij and shaken dry. Wells were blocked with BB2 for 2 h at 25 °C,
washed 2x with NaCl-Brij and shaken dry. Starting dilutions of test
samples were prepared in AD2. Wells of the first row received 200 μL of
the starting dilution and all other wells received 100 μL AD2. Top down
dilutions were prepared by transfer of 100 μL of the diluted sample to
subsequent wells. Plates were covered, incubated overnight at 25 °C,
washed 2x with NaCl-Brij and shaken dry. Hundred μL of AP conjugated
goat anti-human IgG (Sigma) diluted 1:5000 in AD2 was added to each
well and incubated at 37 °C for 4 h. Plates were washed 2x with NaCl-
Brij, shaken dry and 100 μL of 4-Nitrophenyl Phosphate disodium salt
hexahydrate substrate (Sigma) in Tris/3mM Mg-buffer (pH 9.8) was
added to each well and incubated at RT for 10–30mins. Plates were
read at OD405nm.
2.6.6. In-house ELISA 4
The procedure carried out by Laboratory 4 is identical to the pro-
cedure for in-house ELISA 1; except for the use of an AP conjugated
mouse anti-human IgG Fc (Abcam, AB99764) diluted 1:5000.
2.6.7. In-house ELISA 5
The procedure carried out by Laboratory 5 is based on Arakere and
Frasch with some modifications [23]. The plate surface is coated with
methylated Human Serum Albumin (mHSA, NIBSC 12/176) followed
by a coat of Vi from C freundii (NIBSC 12/244). In brief, 100 μL of a
mixture consisting 5 μg Vi mL−1 and 5 μg mHSA mL−1 in PBS was used
to coat wells of a microtiter plate (Nunc MaxiSorp). The plate was in-
cubated overnight at 4 °C and washed 3x with PBS-T. Wells were
blocked with 250 μL BB1 for 2 h at 4 °C and washed 3x with PBS-T. Sera
and reference reagents were diluted in AD1. 200 μL each of starting
dilutions was added to appropriate wells and 100 μL AD1 was added to
the remaining wells. Doubling dilutions were performed on the plate.
Plates were covered and incubated for 2 h at RT and washed three
times. 100 μL HRP conjugated goat anti-human IgG (Sigma) diluted
1:10,000 in AD1 was added to each well. Plates were covered, in-
cubated for 1 h at RT and washed 3x with PBS-T. 100 μL of TMBlue
substrate (Leinco Technologies) was added to each well. Plates were
developed in the dark for 10mins and the reaction was stopped with
50 μL 2M H2SO4 per well. Plates were read at OD450nm.
Table 2
Format of Vi ELISAs used by participants.
Laboratory code ELISA method Vi characteristics Antigen coating procedure
Name Format Status Biological origin
1, 2, 3, 4, 5, 6,7 VaccZyme Indirect – S Typhi Non-disclosed procedure
1, 2, 3, 4, 5, 6,7 NIBSC Capture Biotinylated C freundii Streptavidin coat to bind biotinylated Vi
1 In-house Indirect Naive S Typhi Pre-coat with poly–L-Lysine to bind Vi
2 In-house Indirect Naive C freundii Vi coat only
3 In-house Indirect Naive C freundii Vi coat only
4 In-house Indirect Naive S Typhi Pre-coat with poly–L-Lysine to bind Vi
5 In-house Indirect Naive C freundii Mix coat with mHSA and Vi
6 In-house Capture Biotinylated S Typhi Streptavidin coat to bind biotinylated Vi
7 In-house Indirect Naive S Typhi Vi coat only
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2.6.8. In-house ELISA 6
The procedure carried out by Laboratory 6 is a minor modification
of the ELISA described by Ferry et al. [23]. The plate surface is coated
with streptavidin to capture biotinylated Vi from S Typhi (Fina Bioso-
lutions LLC). In brief, streptavidin from S avidinii (Sigma, S4762) was
prepared in a solution of 3 μgmL−1 and 100 μL was added to each well
of flat bottom microtiter plates (Nunc Maxisorp) and incubated un-
covered at 37 °C overnight, allowing the solution to evaporate to dry-
ness. Pre-coated plates were stored at 4 °C until used for coating. For
antigen coating, 2 μgmL−1 of biotinylated S. Typhi Vi PS produced
locally was prepared in PBS (pH 7.4) and 100 μL was added to the wells
of pre-treated plates. Plates were incubated for 3 h at 37 °C and washed
with PBS-T and wells were blocked overnight with 250 μL PBS con-
taining 10% non-fat dry milk at 4 °C. Plates were washed 6x with PBS-T
with two mins soaking period in between washes. Sera and reference
reagents were diluted in AD1 and added to the plates. All plates were
incubated for 1 h at 37 °C. Following incubation and washing as de-
scribed above, plates were incubated with HRP-labelled goat anti-
Human IgG (Jackson Immunoresearch, 109-035-008) diluted in AD1
for 1 h at 37 °C. The plates were washed 6x with PBS-T, and 100 μL of
TMB Microwell Peroxidase Substrate (KPL, SeraCare Life Sciences Inc)
was added to each well, incubating for 15mins in the dark (with agi-
tation). The reaction was stopped by adding 100 μL of 1M Phosphoric
acid per well. Plates were read immediately at OD450nm.
2.6.9. In-house ELISA 7
The procedure carried out by Laboratory 7 is a modification of the
ELISA by Szu et al. [18]. The plate surface is coated with directly with
Vi PS from S. Typhi (lot 201308, Wuhan Institute of Biological Products
Co. Ltd). Wells (Costar, 2592) were coated with 100 μL of 2 μg Vi mL−1
in PBS diluted from 1mgmL−1 in Milli-Q. Plates were covered, in-
cubated overnight at 4 °C, washed 5x with 1% Brij L23 in 0.8% NaCl
(NaCl-Brij 23). Wells were blocked with BB2 for 2 h at 37 °C, washed 5x
with NaCl-Brij 23 and shaken dry. Starting dilutions of test samples
were prepared in BB2 with 0.1% Brij L23 (AD4). Wells of the first row
received 200 μL of the starting dilution and all other wells received
100 μL AD4. Top down dilutions were prepared by transfer of 100 μL of
the diluted sample to subsequent wells. Plates were covered, incubated
overnight at 25 °C, washed 5x with NaCl-Brij 23 and shaken dry.
Hundred μL of AP conjugated goat anti-human IgG (Southern Biotech,
2040-04) diluted 1:2000 in AD4 was added to each well and incubated
at 37 °C for 2 h. Plates were washed 5x with NaCl-Brij 23 and shaken
dry and 100 μL of 4-Nitrophenyl Phosphate disodium salt hexahydrate
substrate (Sigma, 71768) in Tris/3mM Mg-buffer (pH 9.8) was added
to each well and incubated at RT for 90–120mins, then stopped by
50 μL 3M NaOH. Plates were read at OD405nm.
2.7. Statistical analysis
Raw data from all participants were analysed at NIBSC using a four-
parameter logistic model (sigmoid curves) or a parallel line model.
Assay responses were log transformed and analysis was performed
using EDQM CombiStats Software Version 5.0 [27]. Fitted models
(Sigmoid Curve or Parallel Line) were used to estimate the potency of
coded samples A-E relative to candidate IS 16/138 and U.S. reference
reagent Vi-IgGR1, 2011 and the potency of the two reference standards
relative to each other. Parallelism of dose-response relationships was
concluded if the slope ratio calculated by CombiStats was within the
range 0.80–1.25 and no relative potency was reported where this was
not the case.
All mean results shown in this report are unweighted geometric
means (GM). Variability has been expressed using geometric coeffi-
cients of variation (GCV={10s-1}×100% where s is the standard
deviation of the log10 transformed estimates). Individual assay esti-
mates of relative potency were log transformed and a mixed effects
model used to determine intra-laboratory and inter-laboratory variance
components (also expressed as %GCV) for each sample in NIBSC and
VaccZyme ELISAs.
Further assessment of agreement in geometric mean results for each
pair of laboratories was performed by calculating Lin's concordance
correlation coefficient with log transformed data, although should be
noted that these values are only based on a small number of samples
(n=6) in each case. Calculations were performed using the R package
‘DescTools’.
3. Results
3.1. ELISA performance
All participants reported positive results for 16/138, Vi-IgGR1, 2011
Table 3
Potency estimates relative to 16/138 for U.S. reference reagent Vi-IgGR1, 2011 and coded samples A to E.
Method Sample GMa Overall GM Inter-lab GCVb Intra-lab GCV
Laboratory code 1 2 3 4 5 6 7
NIBSC ELISA Vi-IgGR1, 2011 2.80 – – 3.50 2.61 3.75 1.80 2.80 31% 22%
A 1.34 – – 1.47 1.62 1.70 1.15 1.44 16% 10%
B 0.73 – – 0.77 0.74 1.03 0.73 0.79 15% 11%
C 0.85 – – 0.92 0.90 1.21 1.07 0.98 15% 13%
D 0.46 – – 0.50 0.66 0.25 0.25 0.39 54% 20%
E 0.33 – – 0.39 0.38 0.43 0.60 0.42 25% 10%
VaccZyme ELISA Vi-IgGR1, 2011 1.60 2.02 1.60 1.59 1.39 1.63 – 1.63 11% 13%
A 0.84 1.04 1.18 1.09 1.23 1.21 – 1.09 15% 10%
B 0.27 0.48 0.47 0.41 0.31 0.39 – 0.38 24% 9%
C 0.70 0.97 1.01 1.08 0.94 1.22 – 0.97 20% 11%
D 0.21 0.18 0.25 0.31 0.31 0.29 – 0.25 24% 14%
E 0.44 0.60 0.65 0.71 0.66 0.69 – 0.62 19% 13%
In-house ELISA Vi-IgGR1, 2011 1.88 – – 1.89 1.70 5.18 – – – –
A 0.93 – – 1.17 1.09 1.51 – – – –
B 0.46 – – 0.41 0.53 1.25 – – – –
C 1.04 – – 1.01 0.90 1.15 – – – –
D 0.22 – – 0.33 0.23 0.14 – – – –
E 0.68 – – 0.66 0.47 0.42 – – – –
-: No data entered.
GCV≥25%: Font in Bold.
a GM: Geometric Mean.
b GCV: Geometric Coefficient of Variation.
S. Rijpkema et al. Biologicals 56 (2018) 29–38
33
and samples A-E in all ELISAs, whereas sample F gave negative results
in most ELISAs (See Tables 3 and 4). In the majority of cases, valid
estimates were obtained for the potency of coded samples A-E relative
to 16/138 or U.S. reference reagent Vi-IgGR1, 2011 and for the relative
potency of the two reference reagents to each other.
For inclusion in further analysis, raw ELISA data had to meet criteria
for linearity, parallelism and an intra-laboratory GCV of< 25%. Results
of six ELISAs were not included for the following reasons: the NIBSC
ELISA of Laboratory 2 showed poor repeatability in relative potency
estimates with an average GCV>75% and their in-house ELISA had
insufficient valid data to calculate relative potencies; the results of the
NIBSC ELISA of Laboratory 3 and their in-house did not allow potency
estimates to be calculated by parallel line analysis, because the dose-
response relationships showed high OD values with no plateau in dose-
response and no linear section covering more than two dilutions; the in-
house ELISA of Laboratory 7 had a high level of assay invalidity (68%)
and the VaccZyme ELISA showed poor repeatability in relative potency
estimates (average GCV>75%). Results of these assays are shown in
supplementary Tables A1 and A2 which contain all individual potency
estimates [28].
The relative potency of 16/138 and sample C (a coded duplicate of
16/138) was generally close to the expected value of 1.00 in most
ELISAs (see Table 3, Fig. 2 and supplementary Table A1), although a
systematic bias was observed in some cases (e.g. VaccZyme ELISAs of
Laboratories 1 and 6). The reasons for this are unclear as the labora-
tories followed the study protocol in all cases and these were not ex-
cluded from the analysis presented in Tables 3 and 5.
Potency estimates for the pre-vaccination serum sample F relative to
16/138 are given in Table 4. Most laboratories found sample F to be
negative for anti-Vi IgG (relative potency ≤0.1). A high relative po-
tency value for sample F was recorded by Laboratory 3 for the NIBSC
ELISA and their in-house ELISA and by Laboratory 2 for their in-house
ELISA.
3.2. Comparison of NIBSC and VaccZyme ELISAs
Table 3 summarises the GM potencies per laboratory, overall GM
potencies, intra-laboratory GCVs and inter-laboratory GCVs. In Fig. 2,
the boxplots show the potency estimates of the study samples in NIBSC
and VaccZyme ELISAs relative to 16/138. Inter-laboratory and intra-
laboratory variability, given in Table 3, was generally higher in the
NIBSC ELISA (GCV∼26% using 16/138, ∼35% using Vi-IgGR1, 2011)
compared to VaccZyme (∼19% using 16/138, ∼23% using Vi-IgGR1,
2011). A similar outcome was observed when Vi-IgGR1, 2011 was used as
reference [28].
For the study samples, no agreement in relative potencies was ob-
served between the NIBSC and VaccZyme ELISAs (See Table 3). The
coded samples are shown in decreasing order of potency in the Vacc-
Zyme ELISA in Fig. 2. Note that a different ranking of the coded samples
is observed for the NIBSC ELISA.
3.3. Concordance between NIBSC, VaccZyme and in-house ELISAs
The concordance correlation coefficients for all individual assay
pairs using 16/138 as reference standard is shown in Table 5. Values
of> 0.80 have been highlighted to show where better agreement be-
tween assays was observed. Scatterplots for assay pairs with fitted
Deming regression lines included on each plot are shown in Figs. 3 and
4. Agreement between the VaccZyme ELISA and in-house ELISAs per-
formed by Laboratories 1, 4 and 5 is evident from Figs. 3 and 4 and
Table 5. No or limited concordance was seen for the VaccZyme ELISA
and the NIBSC ELISA in Table 5 and Figs. 3 and 4. A similar outcome
was observed when Vi-IgGR1, 2011 was used as reference standard [28].
Individual potency estimates relative to 16/138 and Vi-IgGR1, 2011 ob-
tained by in-house ELISAs 1, 4 and 5 revealed that data produced by
ELISA 1 and 4 are more robust in terms of parallelism and intra-test
GCV compared to data from ELISA 5 (supplementary Tables A1 and A2
[28]).
Table 4
Potency estimates for sample F relative to 16/138.
Method GMa
Laboratory code 1 2 3 4 5 6 7
NIBSC ELISA 0.05 0.10 0.89b 0.06 0.04 0.10 0.07
VaccZyme ELISA 0.02 0.02 0.02 0.02 0.02 0.02 0.01
In-house ELISA 0.03 0.36 1.14b 0.02 0.01 0.02 0.08
a Geometric Mean.
b Italicized entries represent original data from the participant not calculated
by NIBSC.
Fig. 2. Boxplot of potencies of samples Vi-IgGR1, 2011 and A to E relative to 16/138 in NIBSC and VaccZyme ELISAs.
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Table 5
Concordance correlation coefficients (ρC) for log potencies of Vi-IgGR1, 2011 and samples A to E relative to 16/138.
Fig. 3. Scatterplots of log potencies relative to 16/138 in VaccZyme (Vacc) and in-house ELISAs (IH) for individual lab pairs; solid line indicates agreement, dashed
line indicates fitted Deming regression.
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3.4. Potency estimates for Vi-IgGR1, 2011 and 10/126 relative to 16/138
Potency estimates were calculated for Vi-IgGR1, 2011 and 10/126
relative to 16/138 are summarised in Table 6. The overall GM potency
of Vi-IgGR1, 2011 calculated relative to 16/138 in the VaccZyme ELISA is
1.63 (95% confidence limits 1.44 to 1.85; n=6), which is equivalent to
163 IU mL−1 if 16/138 is assigned an arbitrary unitage of 100 IU per
ampoule (or 100 IU mL−1). Inclusion of the in-house ELISAs by La-
boratories 1, 4 and 5 gives an estimate of 1.69 (95% confidence limits
1.55 to 1.85; n=9). As shown in Table 6, the overall values were not
affected by the inclusion of sample C (coded duplicate of 16/138) in
these calculations. The level of agreement in potency estimates ob-
tained for coded samples A-E when calculated relative to 16/138 (as-
signed 100 IU per ampoule) or relative to Vi-IgGR1, 2011 (assigned 163
IU mL−1) is shown in Fig. 5.
The GM potency of 10/126 calculated relative to 16/138 in the
VaccZyme ELISA is 1.09 (95% confidence limits 0.94 to 1.27; n=6) or
54 IU per ampoule equivalent to 109 IU mL−1, if 16/138 is assigned a
unitage of 100 IU per ampoule. Inclusion of the in-house ELISAs by
Laboratories 1, 4 and 5 gives an estimate of 1.08 (95% confidence limits
0.98 to 1.19; n=9). The GM potency of 10/126 calculated relative to
Vi-IgGR1, 2011 is 0.67 in the VaccZyme ELISA (n=6), which is close to
the value of 0.65 reported previously [15].
3.5. Stability studies
Freeze dried samples of 16/138 were stored for 8.8 months at
Fig. 4. Scatterplots of log potencies relative to 16/138 in NIBSC and in-house ELISAs (IH) for individual lab pairs; solid line indicates agreement, dashed line
indicates fitted Deming regression.
Table 6
Potency estimates for U.S. reference reagent Vi-IgGR1, 2011, the coded duplicate
of 16/138 and 10/126 relative to 16/138.
Method Lab
code
Sample C
(16/138)
Vi-IgGR1, 2011 Sample A (10/
126)
VaccZyme ELISA 1 0.70 1.60 0.84
2 0.97 2.02 1.04
3 1.01 1.60 1.18
4 1.08 1.59 1.09
5 0.94 1.39 1.23
6 1.22 1.63 1.21
In-house ELISA 1 1.04 1.88 0.93
4 1.01 1.89 1.17
5 0.90 1.70 1.09
GMa by VaccZyme ELISA (95% CIb) 1.63
(1.44–1.85)
1.09 (0.94–1.27)
GM by all ELISAs (95% CI) 1.69
(1.55–1.85)
1.08 (0.98–1.19)
GM by VaccZyme ELISA based on potency
relative to both 16/138 and sample C
(95% CI)
1.65
(1.41–1.92)
1.10 (1.01–1.21)
GM by all ELISAs based on potency relative to
both 16/138 and sample C (95% CI)
1.71
(1.55–1.89)
1.09 (1.01–1.18)
a Geometric Mean.
b Confidence Interval.
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−20 °C and at elevated temperatures: +4 °C, +20 °C, +37 °C and
+45 °C. Two ampoules of 16/138 exposed to each temperature were
tested in duplicate by Laboratory 5 in the VaccZyme ELISA, the NIBSC
ELISA and the mHSA Vi ELISA. The potencies relative to samples stored
at −20 °C are given in Table 7.
The results were analysed by DEGTEST-R (in-house NIBSC software)
and used to fit Arrhenius equations relating the degradation rate to
absolute temperature assuming first-order decay and hence predict the
degradation rates when stored at −20 °C [29]. Only results of the
VaccZyme ELISA gave a predicted loss of activity for 16/138 stored at
−20 °C of 0.002% per year. The data from the NIBSC ELISA were
analysed but the chi-squared test for goodness of fit showed these not to
fit the model (results not shown). The relative potencies are shown for
information only. Data from the mHSA Vi ELISA could not be analysed
due to the non-linearity of the dose responses curves (results not
shown).
4. Discussion
The results of the collaborative study demonstrate that 16/138 is
suitable as an IS for anti-Vi IgG serum (human) in various ELISA for-
mats used in Vi serology, where the commutability of 16/138 with
coded test samples A-E and Vi-IgGR1, 2011 was evident in the VaccZyme
ELISA and in-house ELISAs by Laboratories 1, 4 and 5.
The outcomes for assay validity, variability in potency estimates,
agreement between methods and laboratories are similar for both 16/
138 and Vi-IgGR1, 2011. Based on the commercial VaccZyme ELISA,
ECBS assigned an arbitrary unitage of 100 IU anti-Vi IgG per ampoule of
16/138, and a relative potency of 163 IU per vial of Vi-IgGR1, 2011 [28].
A study of human volunteers, vaccinated with the same vaccines as this
study (TCV or Vi-PS) and challenged with a high dose of S Typhi,
showed an efficacy of 52–54.6% [24]. Although, the challenge study by
Jin et al. did not identify a threshold of protection for anti-Vi IgG titres,
logistic regression modelling showed that high anti-Vi IgG titres were
associated with a lower probability of typhoid fever infection in this
model [24]. The challenge model likely underestimates field efficacy
(as discussed by Jin et al.), we therefore propose that the moderate to
high level of anti-Vi IgG detected in 16/138 can be associated with a
lower risk of acquiring typhoid fever, enhancing the value of 16/138 as
a benchmark for assays used for the evaluation of clinical trial studies of
new and existing TCV formulations.
10/126, the previous candidate IS, was included as a coded test
sample and the estimated potency relative to Vi-IgGR1, 2011 by
VaccZyme ELISA showed excellent agreement with the value reported
in the previous collaborative study [15]. This confirms the outcome of
the current study and further supports the use of 10/126 as a working
standard. Based on the commercial ELISA, ECBS assigned a relative
potency of 54 IU per ampoule of 10/126, which is equivalent to 109 IU
mL−1 [28].
In-house ELISAs 2, 3 and 7, which coat unaided Vi to the plate
surface were not robust and did not perform well in this study. These
assays showed high levels of variability and poor linearity of the dose
response curve.
Good concordance was seen between the VaccZyme ELISA and in-
house ELISAs 1, 4 and 5. The study results indicate that the NIBSC
ELISA, despite a good performance is unsuitable as a an alternative for
the commercial ELISA as no agreement in relative potency estimates or
ranking of coded test samples was observed between the two types of
ELISA. Indeed, concordance was lacking between the commercial
VaccZymeˆ ELISA and both ELISAs based on biotinylated Vi: the NIBSC
ELISA and the in-house ELISA of Laboratory 6. We attribute this dif-
ferentiation to the choice of coating procedures for Vi: in-house ELISAs
1, 4 and 5 use a protein to enhance the binding of native Vi to the plate
surface. Whereas the modification of Vi through biotinylation seems to
have altered the presentation of the Vi antigen on the plate surface,
resulting in a different population of anti-Vi IgG being detected.
Unfortunately, the coating procedure for Vi used in the VaccZymeˆ
ELISA remains unknown and therefore this observation cannot be
verified.
We conclude that either in-house ELISA 1, 4 or 5 could be an al-
ternative for the VaccZyme ELISA. The in-house ELISA of Laboratory 1
has two advantages compared with in-house ELISA 5: the procedure
was successfully transferred to Laboratory 4; and a detailed analysis of
data from in-house ELISA 1 and 4 showed improved parallelism and
assay precision for the study samples. Therefore, a follow-up multi la-
boratory study with in-house ELISA 1 will be initiated to demonstrate if
this format can become the consensus assay and an alternative for the
commercial ELISA.
To summarise our results: 16/138 contains a freeze-dried residue of
a post-vaccination serum pool with a potency of 100 IU anti-Vi IgG per
ampoule. The fill met WHO specifications, is stable and 16/138 is
suitable as an IS for anti-Vi IgG (human) in various ELISA formats.
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